

2020

Injection drug use and care charges for infective endocarditis

Verity N. Ramirez
Maine Medical Center

Et al.

Follow this and additional works at: <https://knowledgeconnection.mainehealth.org/jmmc>



Part of the [Epidemiology Commons](#), [Infectious Disease Commons](#), and the [Substance Abuse and Addiction Commons](#)

Recommended Citation

Ramirez, Verity N.; Carwile, Jenny L.; Rokas, Kristina; Craig, Wendy; and Thakarar, Kinna (2020) "Injection drug use and care charges for infective endocarditis," *Journal of Maine Medical Center*. Vol. 2 : Iss. 1 , Article 12.

Available at: <https://knowledgeconnection.mainehealth.org/jmmc/vol2/iss1/12> <https://doi.org/10.46804/2641-2225.1029>

The views and thoughts expressed in this manuscript belong solely to the author[s] and do not reflect the opinions of the Journal of Maine Medical Center or MaineHealth.

This Research and Quality Improvement Brief is brought to you for free and open access by Maine Medical Center Department of Medical Education. It has been accepted for inclusion in the Journal of Maine Medical Center by an authorized editor of the MaineHealth Knowledge Connection. For more information, please contact Dina McKelvy mckeld1@mmc.org.

Injection drug use and care charges for infective endocarditis

Acknowledgements

Acknowledgements 1. We thank the staff at the Maine Medical Center Billing department for their assistance in obtaining billing data. 2. There is no funding source for this manuscript. 3. We presented our data as a poster at the Maine Center for Disease Control Infectious Disease Conference in Augusta, ME, in November 2017.

Authors

Verity N. Ramirez, Jenny L. Carwile, Kristina Rokas, Wendy Craig, and Kinna Thakarar

RESEARCH LETTER**Injection drug use and care charges for infective endocarditis**

Verity N. Ramirez, MD,¹ Jenny L. Carwile, ScD, MPH,¹ Kristina Rokas, PharmD,² Wendy Craig, PhD,³ Kinna Thakarar, DO, MPH⁴

¹Department of Internal Medicine, Maine Medical Center, Portland, ME, ²Maine Medical Center, Portland, ME, ³Maine Medical Center Research Institute, Scarborough, ME, ⁴Department of Infectious Disease, Maine Medical Center, Portland, ME

Keywords: infective endocarditis, intravenous drug use, hospital charges, injection drug use

Rates of infective endocarditis (IE), an infection that can result from injection-drug use (IDU), have risen alongside the opioid epidemic.¹⁻³ While previous studies have characterized hospitalizations for injection drug use-related IE,^{3,4} comparing hospitalization characteristics between people who inject drugs (PWID) and non-PWID may explain different outcomes between IE patients. It could also be used to inform the development of cost-effective optimal care models, which may differ between PWID^{5,6} and non-PWID. Here, we compare inpatient hospitalization characteristics, including care charges, between PWID and non-PWID with IE at a large academic medical center.

METHODS

We performed a cross-sectional analysis of adult patients (≥ 18 years old) diagnosed with IE and admitted to a Maine Medical Center (Portland, ME) between January 1, 2013 and January 1, 2016. IE was defined by Duke's criteria as definite or possible endocarditis on transesophageal echocardiograms. Patients were classified as PWID if IDU or clinical suspicion of IDU was documented in the electronic medical record (EMR). Only the first admission for IE during the study period was included.

For each admission, we retrospectively obtained data from the hospital's billing department, including total hospital charges (e.g., surgery, anesthesia, stay in the intensive care unit, antibiotics), amount paid by insurance, and outstanding hospital charges. For insured patients, insurance paid 100%

Correspondence: Kinna Thakarar, DO, MPH
Maine Medical Center, Department of Infectious Disease
22 Bramhall St, Portland, ME 04102
KThakarar@mmc.org

of total charges. We obtained EMR data on patient demographics, insurance status, length of stay (LOS), in-hospital mortality, and cardiac surgery during the hospitalization.

We summarized variables as mean [standard deviation (SD)], median (range), or frequency. We compared characteristics between PWID and non-PWID using Mann-Whitney U tests, Student's t-tests, chi-square tests, or Fisher's exact tests. We used SPSS, version 25 (Armonk, NY) for all analyses. The Maine Medical Center Institutional Review Board approved this study.

RESULTS

We identified 42 cases of IE among PWID (39%) and 65 among non-PWID (61%). PWID were younger (mean [SD]: 34.8 [9.1] vs. 63.1 [15.7] years; $P < .001$), less likely to have a primary care provider (71.4% vs. 89.2%, $P = .04$), and had a different insurance payer distribution ($P < .001$) than non-PWID (Table 1). PWID had a longer LOS (median: 18.4 vs 11.9 days) and were more likely to complete their intravenous antibiotics in the hospital (35.7% vs. 4.6%) compared to non-PWID.

Median total hospital charges were \$149,131 (range: \$16,282-\$630,151) for PWID and \$80,903 (range: \$16,902-\$736,328) for non-PWID ($P = .08$; Figure 1). Among patients with IE, total charges per day paid by insurance did not vary between PWID [median: \$6,924 (range: \$3,778-25,803)] and non-PWID [median: \$7,212 (range: \$259-97,147)] ($P = .99$). Among insured IE patients, total hospital charges paid by insurance were significantly higher for PWID [median: \$174,573 (range: \$16,282-\$630,151)] than non-PWID [median: \$80,903

(range: \$16,902-\$736,328)] (P = .03). Of the 11 uninsured PWID, five received a hospital write-off of their bill, totaling \$414,886 (median: \$53,621 per patient). Six uninsured PWID and two uninsured non-PWID had non-covered hospital charges (median: \$105,401 and \$83,678 per patient, respectively).

DISCUSSION

Among patients hospitalized for IE, median total hospital charges and charges paid by insurance were approximately twice as high for PWID as non-PWID. Higher charges among PWID resulted from their longer LOS, which may be due to more frequent completion of antibiotic treatment before hospital discharge. At our institution and others, a common practice is to not discharge PWID with a peripherally inserted central catheter (PICC) line due to concerns related to risk of line misuse and subsequent infection.^{7,8} Similarities in daily hospital

charges and cardiac surgery requirements between PWID and non-PWID suggest that intensity of care did not differ by IDU. Outpatient antibiotic management, which was not included, represents an additional cost.

Over a three-year period at a single hospital, median charges for IE hospitalization among PWID exceeded those for non-PWID by \$63,228. Despite our study's limitations (i.e., potential misclassification of PWID and inclusion of a single hospital), these data suggest that IDU-associated IE creates an additional financial burden to hospitals, payers, and the patient. Future research should investigate optimal models of care (e.g., medical respite, patient-directed discharges) for administering antibiotics to PWID with infections. Finally, improving access to medication for addiction treatment and harm reduction strategies may prevent serious bacterial complications associated with IDU.




Figure 1. Box plots for hospital charges associated with infective endocarditis among people who inject drugs (PWID) and non-PWID.

Box =25th and 75th percentiles; bars = min and max values.

*Among patients with insurance (n=31 PWID; n=63 non-PWID)

†Mann-Whitney U test, p=0.08

‡Mann-Whitney U test, p=0.03

Abbreviations: PWID, people who inject drugs

Table 1. Characteristics of 107 infective endocarditis patients by injection drug use.

	Injection drug use, N (%)		p-value
	Yes	No	
N (%)	42 (39.3)	65 (60.7)	
Age (years), mean (SD)	34.8 (9.1)	63.1 (15.7)	<0.001*
Male	27 (64.3)	47 (72.3)	0.51
Race			
Caucasian	41 (97.6)	62 (95.4)	
Black	0 (0.0)	1 (1.5)	
Unknown	1 (2.4)	2 (3.1)	
Had primary care provider	30 (71.4)	58 (89.2)	0.04
Length of stay (days), median (range)	18.4 (2.2-86.7)	11.9 (0.2-101.4)	0.02
Cardiac surgery during admission	14 (33.3)	17 (26.2)	0.56
Discharged with IV antibiotics via PICC	17 (40.5)	51 (78.4)	<0.001
Discharge Disposition†			<0.001
Home with PICC	12 (28.6)	30 (46.2)	
Care Facility with PICC	3 (7.1)	16 (24.6)	
Deceased/CMO	4 (9.5)	10 (15.4)	
Left early (i.e. against medical advice) without PICC	5 (11.9)	0 (0.0)	
Completed antibiotics in hospital	15 (35.7)	3 (4.6)	
Unknown	3 (7.1)	6 (9.2)	
Insurance payer			<0.001
Private only	1 (2.4)	18 (27.7)	
Medicaid only	25 (59.5)	13 (20.0)	
Medicare only	4 (9.5)	19 (29.2)	
>1 Insurance	1 (2.4)	13 (20.0)	
Uninsured	11 (26.2)	2 (3.1)	

Abbreviations: CMO, comfort measures only; PICC, peripherally inserted central catheter

*p-values calculated using t-test, Fisher's exact test, Mann-Whitney U test, and Chi square test with continuity correction as appropriate.

†Percentages do not sum to 100% due to rounding.

Acknowledgements: We thank the staff at the Maine Medical Center Billing department for their assistance in obtaining billing data.

Conflicts of Interest: None

REFERENCES

1. Fleischauer AT, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010-2015. *MMWR Morb Mortal Wkly Rep.* 2017;66(22):569-573. doi: 10.15585/mmwr.mm6622a1
2. Wurcel AG, Anderson JE, Chui KK, et al. Increasing infectious endocarditis admissions among young people who inject drugs. *Open Forum Infect Dis.* 2016;3(3):ofw157. doi: 10.1093/ofid/ofw157
3. Ronan MV, Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2000-2015. *Am J Public Health.* 2016;106(10):1837. doi: 10.1377/hlthaff.2015.1424.
4. Fleischauer A, Ruhl L, Rhea S, Barnes E. Hospitalizations for endocarditis and associated health care costs among persons with diagnosed drug dependence - North Carolina, 2010-2015. *MMWR Morb Mortal Wkly Rep.* 2017;66(22):569-573. doi: 10.15585/mmwr.mm6622a1.
5. Fanucchi LC, Walsh SL, Thornton AC, Lofwall MR. Integrated outpatient treatment of opioid use disorder and injection-related infections: A description of a new care model. *Prev Med.* 2019;105760. doi: 10.1016/j.ypmed.2019.105760
6. Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-acting lipoglycopeptides: "Lineless antibiotics" for serious infections in persons who use drugs. *Open Forum Infect Dis.* 2019;6(7):ofz274. doi: 10.1093/ofid/ofz274
7. Fanucchi L, Leedy N, Li J, Thornton AC. Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs. *J Hosp Med.* 2016;11(8):581-582. doi: 10.1002/jhm.2582
8. Suzuki J, Johnson J, Montgomery M, Hayden M, Price C. Outpatient parenteral antimicrobial therapy among people who inject drugs: A review of the literature. *Open Forum Infect Dis.* 2018;5(9):ofy194. doi: 10.1093/ofid/ofy194